Top Markets
Coin of the day
Achilles Therapeutics plc Achilles Therapeutics plc

Achilles Therapeutics plc

ACHL
Clasificación en acciones #24575
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused... Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
Precio por acción
$1.48
Última sincronización: 2025-03-24
Capitalización bursátil
$59.05M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
GB
Comercio Achilles Therapeutics plc (ACHL)

Categoría

Historial de rendimiento por dividendo de Achilles Therapeutics plc (ACHL)
Rendimiento por dividendo (TTM) de Achilles Therapeutics plc (símbolo bursátil: ACHL) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Achilles Therapeutics plc (ACHL) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH